NO317720B1 - Anvendelse av en defektiv, rekombinant adenovirus for fremstilling av preparater mot restenose og aterosklerose - Google Patents

Anvendelse av en defektiv, rekombinant adenovirus for fremstilling av preparater mot restenose og aterosklerose Download PDF

Info

Publication number
NO317720B1
NO317720B1 NO19961504A NO961504A NO317720B1 NO 317720 B1 NO317720 B1 NO 317720B1 NO 19961504 A NO19961504 A NO 19961504A NO 961504 A NO961504 A NO 961504A NO 317720 B1 NO317720 B1 NO 317720B1
Authority
NO
Norway
Prior art keywords
adenovirus
gene
use according
killer
hydrogel
Prior art date
Application number
NO19961504A
Other languages
English (en)
Norwegian (no)
Other versions
NO961504D0 (no
NO961504L (no
Inventor
Michel Perricaudet
Didier Branellec
Jean-Francois Dedieu
Patrice Denefle
Laurent Feldman
Gabriel Steg
Original Assignee
Gencell Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gencell Sa filed Critical Gencell Sa
Publication of NO961504D0 publication Critical patent/NO961504D0/no
Publication of NO961504L publication Critical patent/NO961504L/no
Publication of NO317720B1 publication Critical patent/NO317720B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01021—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NO19961504A 1994-08-17 1996-04-16 Anvendelse av en defektiv, rekombinant adenovirus for fremstilling av preparater mot restenose og aterosklerose NO317720B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9410083A FR2723697B1 (fr) 1994-08-17 1994-08-17 Methode de traitement de la restenose par la therapie genique
PCT/FR1995/001074 WO1996005321A1 (fr) 1994-08-17 1995-08-10 Therapie genique de la restenose au moyen de vecteur adenovial

Publications (3)

Publication Number Publication Date
NO961504D0 NO961504D0 (no) 1996-04-16
NO961504L NO961504L (no) 1996-04-16
NO317720B1 true NO317720B1 (no) 2004-12-02

Family

ID=9466347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19961504A NO317720B1 (no) 1994-08-17 1996-04-16 Anvendelse av en defektiv, rekombinant adenovirus for fremstilling av preparater mot restenose og aterosklerose

Country Status (12)

Country Link
US (2) US6410011B1 (fr)
EP (1) EP0734448A1 (fr)
JP (1) JPH09504558A (fr)
AU (1) AU3169495A (fr)
CA (1) CA2174232A1 (fr)
FI (1) FI961666L (fr)
FR (1) FR2723697B1 (fr)
IL (1) IL114982A (fr)
MX (1) MX9601368A (fr)
NO (1) NO317720B1 (fr)
WO (1) WO1996005321A1 (fr)
ZA (1) ZA956849B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
US5985320A (en) * 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US6387390B1 (en) 1998-10-05 2002-05-14 The Penn State Research Foundation Compositions and methods for enhancing receptor-mediated cellular internalization
DE19620308A1 (de) * 1996-05-10 1997-11-13 Franz Wolfgang M Dr Vektor-System zur spezifischen in vivo Genexpression in glatten Gefäßmuskelzellen
US7232899B2 (en) * 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6398757B1 (en) 1997-02-07 2002-06-04 Leuven Research & Development Vzw Gene therapeutic treatment of blood vessel associated disorders
US6087164A (en) 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
CA2319112C (fr) 1998-02-13 2003-10-28 Genetrace Systems, Inc. Utilisation de ribozymes afin d'identifier la fonction de genes
WO2000052186A1 (fr) * 1999-03-04 2000-09-08 Introgene B.V. Transduction de cellules ressemblant a des fibroblastes ou a des macrophages et moyens a cet effet
US7052904B2 (en) 2000-01-31 2006-05-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hybrid adeno-retroviral vector for the transfection of cells
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US7226779B2 (en) * 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
US7485318B2 (en) * 2001-04-04 2009-02-03 Delsitech Oy Biodegradable carrier and method for preparation thereof
WO2003083105A1 (fr) * 2002-03-28 2003-10-09 Medicalseed Co., Ltd. Traitement et prevention de l'angiostenose
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
WO2011032100A1 (fr) 2009-09-11 2011-03-17 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Inhibiteurs du kshv vil6 et il6 humain
WO2018022511A1 (fr) 2016-07-25 2018-02-01 The Trustees Of The University Of Pennsylvania Compositions comprenant un variant de la lécithine-cholestérol-acyl-transférase et leurs utilisations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO1993008845A1 (fr) * 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Traitement par application localisee d'oligonucleotides
DE69331526T2 (de) * 1992-11-18 2002-10-24 Arch Development Corp., Chicago Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel
WO1994027612A1 (fr) * 1993-05-20 1994-12-08 Baylor College Of Medicine Therapie genetique contre une maladie cardiovasculaire
CA2144040A1 (fr) * 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
US6682728B1 (en) * 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima
EP0804249A2 (fr) * 1994-03-15 1997-11-05 Brown University Research Foundation Systeme de liberation de genes polymeres
US6780406B1 (en) * 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy

Also Published As

Publication number Publication date
WO1996005321A1 (fr) 1996-02-22
US20020094324A1 (en) 2002-07-18
FI961666A7 (fi) 1996-06-06
IL114982A (en) 2006-10-31
US6410011B1 (en) 2002-06-25
FI961666L (fi) 1996-06-06
ZA956849B (en) 1996-04-15
FR2723697B1 (fr) 1996-09-20
FR2723697A1 (fr) 1996-02-23
NO961504D0 (no) 1996-04-16
EP0734448A1 (fr) 1996-10-02
FI961666A0 (fi) 1996-04-16
JPH09504558A (ja) 1997-05-06
IL114982A0 (en) 1995-12-08
CA2174232A1 (fr) 1996-02-22
MX9601368A (es) 1998-06-30
NO961504L (no) 1996-04-16
AU3169495A (en) 1996-03-07

Similar Documents

Publication Publication Date Title
Kochanek et al. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase.
US6410011B1 (en) Gene therapy for restenosis using an adenoviral vector
USRE37933E1 (en) Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
US6630344B1 (en) Diminishing viral gene expression by promoter replacement
US6669942B2 (en) Defective adenoviruses including a therapeutic gene and an immunoprotectove gene
EP0787200B1 (fr) Adenovirus ameliore et ses procedes d'utilisation
US7531167B2 (en) Herpes simplex virus vector
AU708870B2 (en) Gene therapy using ovine adenoviral vectors
US6780406B1 (en) Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
US20030219410A1 (en) Adenoviral vectors for modulating the cellular activities associated to PODs
US20040175363A1 (en) Adenovirus comprising a gene coding for glutathione peroxidase
NO317725B1 (no) Rekombinante adenoviruser for genterapi mot cancer
WO1995010623A1 (fr) Transfert selectif adenoviral de genes vers les cellules neointimales vasculaires
JP2002508661A (ja) ウシアデノウイルスタイプ３ゲノム
US20030087867A1 (en) Gene therapy for enhancing and/or inducing angiogenesis
Gojo et al. Gene transfer into the donor heart during cold preservation for heart transplantation
US20040132190A1 (en) Gene therapy for myocardial ischemia
US20020061299A1 (en) Antioxidant gene therapy for myocardial infarction
AU740852B2 (en) Gene therapy for restenosis using an adenoviral vector
JP2005518807A (ja) 筋細胞中の目的とする遺伝子の発現の持続のための発現カセット
US7368553B2 (en) Alternatively spliced nucleic acid molecules
US20030212030A1 (en) Novel adenoviral vector for transferring human genes in vivo
WO1996040195A1 (fr) Therapie genique pour ischemie myocardique
US20050054591A1 (en) Yin yang-1
WO2001044484A1 (fr) Replication conditionnelle d'adn d'adenovirus humain de recombinaison portant des sequences de repetition terminale inverses modifiees